Cyclopharm

US Healthcare Trends Will Accelerate Advanced Technegas Integration

AnalystConsensusTarget

Not Invested

Consensus Narrative from 1 Analyst

Published

07 Sep 25

AnalystConsensusTarget's Fair Value

AU$1.49

44.3% undervalued

07 Sep

AU$0.83

-43.3%

-2.4%

-43.3%

-2.4%

You can edit this narrative until Sep 7 8:14 PM. Then, changes will post as Updates.

Author's Valuation

AU$1.5

44.3% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

AU$1.49

44.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

36.66%

Medical Equipment revenue growth rate

0.40%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.18%

Calculation

AU$7.40m

Earnings '28

27.53x

PE Ratio '28

AU$203.80m

Market Cap '28

AU$203.80m

Market Cap '28

111.14m

No. shares '28

AU$1.83

Share Price '28

AU$1.83 Share Price '28

Discounted to 2025 @ 7.18% p.a.

AU$1.49

Fair Value '25